Stock 688192 DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Dizal (Jiangsu) Pharmaceutical Co., Ltd. Share Price

Equities

688192

CNE1000055W8

Biotechnology & Medical Research

End-of-day quote Shanghai S.E.
Other stock markets
 23:00:00 25/04/2024 BST 		5-day change 1st Jan Change
44.39 CNY +3.26% Intraday chart for Dizal (Jiangsu) Pharmaceutical Co., Ltd. +25.40% -7.23%
04-24 Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer CI
04-07 U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations CI

Financials

Sales 2023 91.29M 12.6M 1.01B Sales 2024 * 490M 67.62M 5.42B Capitalization 18.45B 2.55B 204B
Net income 2023 -1.12B -155M -12.41B Net income 2024 * -649M -89.57M -7.17B EV / Sales 2023 214 x
Net cash position 2023 * - 0 0 Net cash position 2024 * - 0 0 EV / Sales 2024 * 37.7 x
P/E ratio 2023
-17.4 x
P/E ratio 2024 *
-28.5 x
Employees 424
Yield 2023 *
-
Yield 2024 *
-
Free-Float 18.48%
More Fundamentals * Assessed data

Chart Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Dizal Pharmaceutical Co., Ltd. Announces Two Abstracts Featuring the Latest Data on Sunvozertinib in Non-Small Cell Lung Cancer CI
U.S. Food and Drug Administration Grants Breakthrough Therapy Designation to Dizal's Sunvozertinib for the First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations CI
Dizal Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Dizal's Sunvozertinib Pivotal Study Results Published in The Lancet Respiratory Medicine CI
Dizal Pharmaceutical Co., Ltd.(SHSE:688192) added to Shanghai Stock Exchange Health Care Sector Index CI
Dizal's Golidocitinib Pivotal Trial Demonstrates Superior and Durable Clinical Benefits for Patients with r/r PTCL in Oral Presentation at 2023 ASH CI
Dizal Pharma to Invest 700 Million Yuan in New Dermatology Venture MT
Dizal Pharma Presents Positive Results of Lung Cancer Drug MT
Dizal Announces Latest Research Findings on the Efficacy and Safety of Sunvozertinib in Treatment-Naive Patients CI
Chinese Drug Regulator Puts Dizal Pharma's Lymphoma Drug in Priority Review MT
Dizal Pharmaceutical Receives Priority Review by China NMPA for the Treatment of r/r PTCL CI
Dizal Pharmaceutical Co., Ltd.(XSSC:688192) added to S&P Global BMI Index CI
Dizal Pharmaceutical Co., Ltd. Announces China CDE Acceptance of New Drug Application for Golidocitinib for Relapsed or Refractory PTCL CI
Dizal (Jiangsu) Pharmaceutical's Anti-Lymphoma Medication Research Results Published in European Oncology Journal MT
Dizal Pharmaceutical Announces Clinical Results of Golidocitinib Published in Annals of Oncology CI
More news

Quotes and Performance

1 day+3.26%
1 week+25.40%
Current month-1.33%
1 month+1.35%
3 months+20.01%
6 months+23.89%
Current year-7.23%
More quotes

Highs and lows

1 week
34.31
Extreme 34.31
44.40
1 month
34.31
Extreme 34.31
45.83
Current year
24.82
Extreme 24.82
48.83
1 year
24.82
Extreme 24.82
55.33
3 years
19.02
Extreme 19.02
56.12
5 years
19.02
Extreme 19.02
56.12
10 years
19.02
Extreme 19.02
56.12
More quotes

Managers and Directors - Dizal (Jiangsu) Pharmaceutical Co., Ltd.

Managers TitleAgeSince
Xiao Lin Zhang CEO
 Chief Executive Officer 60 26/10/17
Wei Wen Dong CHM
 Chairman 38 31/05/18
Hong Bin Lu DFI
 Director of Finance/CFO 46 30/06/20
Members of the board TitleAgeSince
Simon Lü BRD
 Director/Board Member 56 30/09/17
Xue Gong Wang BRD
 Director/Board Member 52 06/09/20
Guan Shan Zhu BRD
 Director/Board Member 60 07/09/20
More insiders

Quotes

Date Price Change Volume
26/04/24 44.39 +3.26% 2,087,549
25/04/24 42.99 +1.92% 2,988,799
24/04/24 42.18 +0.86% 2,589,122
23/04/24 41.82 +10.99% 3,851,922
22/04/24 37.68 +6.44% 2,325,619

End-of-day quote Shanghai S.E., April 25, 2024

More quotes

Company Profile

Dizal Jiangsu Pharmaceutical Co Ltd is a China-based company mainly engaged in the exploration, research, development and commercialization of innovative biomedicine. The Company focuses on diseases such as malignant tumors and immune diseases. The main candidate innovative drugs in the Company's research and development (R&D) pipeline are DZD4205, DZD9008, DZD1516, DZD2269, DZD8586, DZD0095. The Company is still in the R&D stage.
Sector
Biotechnology & Medical Research
Calendar
29/04/2024 - Q4 2023 Earnings Release
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
44.39 CNY
Average target price
52.16 CNY
Spread / Average Target
+17.49%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. Stock Dizal (Jiangsu) Pharmaceutical Co., Ltd.
-7.23% 2.55B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 688192 Stock